TP53 and neoplasm: Interestingly, it has been recently shown that, in lung cancer, loss-of-function mutations in the tumor suppressor P53 gene are associated with increased expression of PD-L1, immune-cell infiltration, and tumor immunogenicity and may help in predicting response to ICB therapy.45